<DOC>
	<DOC>NCT01367613</DOC>
	<brief_summary>This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.</brief_summary>
	<brief_title>Open-Label Treatment Extension of Protocol MNTX 302</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1. Must be enrolled and consented within 28 days of the end of study visit of MNTX 302 and 14 or more days from first dose of study drug in MNTX 302. 2. Negative pregnancy test 3. Stable vital signs 1. Women who are pregnant and/or nursing 2. Received any investigational product, other than MNTX, in the past 30 days 3. Evidence of fecal impaction 4. Clinically significant active diverticular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Advanced medical illness</keyword>
</DOC>